Neurocrine Biosciences, Inc. (BVMF:N1BI34)
Brazil
· Delayed Price · Currency is BRL 33.57
-1.20 (-3.45%)
At close: Mar 6, 2026
Neurocrine Biosciences Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Net Income | 478.6 | 341.3 | 249.7 | 154.5 | 89.6 | Upgrade
|
| Depreciation & Amortization | 30.1 | 27.1 | 21.3 | 15.6 | 10.9 | Upgrade
|
| Other Amortization | - | - | - | - | 17.3 | Upgrade
|
| Asset Writedown & Restructuring Costs | 0.7 | 14 | - | - | - | Upgrade
|
| Loss (Gain) From Sale of Investments | -8.7 | 10.9 | -46.7 | -27.1 | -13.5 | Upgrade
|
| Stock-Based Compensation | 217.9 | 195.5 | 194.3 | 173.1 | 134.2 | Upgrade
|
| Other Operating Activities | 192.9 | 25.8 | -56.9 | 90.7 | 1.3 | Upgrade
|
| Change in Accounts Receivable | -210.5 | -39.8 | -89.3 | -162.2 | -28.4 | Upgrade
|
| Change in Inventory | -15.3 | -19.1 | 5.4 | -2.6 | -2.5 | Upgrade
|
| Change in Accounts Payable | 160.2 | 43.4 | 49 | 114.6 | 56.8 | Upgrade
|
| Change in Income Taxes | -18.8 | 50.3 | 91.6 | - | - | Upgrade
|
| Change in Other Net Operating Assets | -44.4 | -54 | -28.5 | -17.2 | -9.2 | Upgrade
|
| Operating Cash Flow | 782.7 | 595.4 | 389.9 | 339.4 | 256.5 | Upgrade
|
| Operating Cash Flow Growth | 31.46% | 52.71% | 14.88% | 32.32% | 12.25% | Upgrade
|
| Capital Expenditures | -34 | -38.2 | -28.3 | -16.5 | -23.4 | Upgrade
|
| Cash Acquisitions | - | - | - | -42.7 | - | Upgrade
|
| Investment in Securities | -230.4 | -88.6 | -438.8 | -117.9 | -106.8 | Upgrade
|
| Investing Cash Flow | -264.4 | -126.8 | -467.1 | -177.1 | -130.2 | Upgrade
|
| Long-Term Debt Repaid | - | -308.8 | - | -279 | -0.1 | Upgrade
|
| Net Debt Issued (Repaid) | - | -308.8 | - | -279 | -0.1 | Upgrade
|
| Issuance of Common Stock | 129.4 | 122.1 | 65.3 | 44.7 | 27.5 | Upgrade
|
| Repurchase of Common Stock | -167.7 | -300 | - | - | - | Upgrade
|
| Financing Cash Flow | -38.3 | -486.7 | 65.3 | -234.3 | 27.4 | Upgrade
|
| Foreign Exchange Rate Adjustments | - | - | 0.3 | -1.3 | - | Upgrade
|
| Net Cash Flow | 480 | -18.1 | -11.6 | -73.3 | 153.7 | Upgrade
|
| Free Cash Flow | 748.7 | 557.2 | 361.6 | 322.9 | 233.1 | Upgrade
|
| Free Cash Flow Growth | 34.37% | 54.09% | 11.98% | 38.52% | 7.12% | Upgrade
|
| Free Cash Flow Margin | 26.17% | 23.66% | 19.16% | 21.69% | 20.57% | Upgrade
|
| Free Cash Flow Per Share | 7.30 | 5.37 | 3.58 | 3.27 | 2.38 | Upgrade
|
| Cash Interest Paid | - | 1.6 | 3.8 | 6.6 | 8.6 | Upgrade
|
| Cash Income Tax Paid | 81.4 | 217.5 | 51.5 | 14.4 | 5.1 | Upgrade
|
| Levered Free Cash Flow | 397.81 | 507.33 | 439.25 | 247.63 | 265.75 | Upgrade
|
| Unlevered Free Cash Flow | 397.81 | 507.33 | 439.25 | 247.63 | 264.58 | Upgrade
|
| Change in Working Capital | -128.8 | -19.2 | 28.2 | -67.4 | 16.7 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.